Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases
Identifieur interne : 003976 ( Main/Exploration ); précédent : 003975; suivant : 003977Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases
Auteurs : Douglas G. Walker [Canada, États-Unis] ; Kazuhiro Terai [Canada, Japon] ; Akinori Matsuo [Canada, Japon] ; Thomas G. Beach [Canada, États-Unis] ; Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada]Source :
- Brain Research [ 0006-8993 ] ; 1998.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Cell Survival (physiology), Cell death, Dopamine (analysis), Dopaminergic, Dopaminergic neuron, Female, Fibroblast Growth Factor 1 (analysis), Fibroblast growth factor, Human, Humans, Immunohistochemistry, Locus niger, Male, Middle Aged, Neurodegeneration, Neuron, Neurons (chemistry), Neurotrophic factor, Parkinson Disease (metabolism), Parkinson disease, Reference Values, Substantia Nigra (chemistry), Substantia Nigra (cytology), Tyrosine kinase.
- MESH :
- chemical , analysis : Dopamine, Fibroblast Growth Factor 1.
- chemistry : Neurons, Substantia Nigra.
- cytology : Substantia Nigra.
- metabolism : Parkinson Disease.
- physiology : Cell Survival.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Immunohistochemistry, Male, Middle Aged, Reference Values.
Abstract
The use of neurotrophic growth factors as a means of preventing loss of the dopaminergic (DA) neurons in the substantia nigra (SN) is becoming an accepted treatment strategy for Parkinson's disease (PD). In earlier studies, we showed that there was a selective loss of basic fibroblast growth factor (bFGF) immunoreactivity in DA neurons of the SN in PD suggesting that a deficiency of bFGF might contribute to cell death. As a preliminary step to assessing the potential for using bFGF or its analogs as therapeutic agents, the expression of fibroblast growth factor receptor-1 (FGFR-1) in the SN of normal and PD cases was investigated immunohistochemically. FGFR-1 immunoreactivity could be detected in DA neurons of the SN in young and old neurologically normal cases with an apparent decline with age. FGFR-1 immunoreactivity was also detected in many of the residual SN neurons in most of the idiopathic PD cases. These results indicate that FGFR-1 immunoreactivity, and possibly FGF binding activity, is retained in DA neurons in PD.
Url:
DOI: 10.1016/S0006-8993(98)00132-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002549
- to stream Istex, to step Curation: 002549
- to stream Istex, to step Checkpoint: 001534
- to stream Main, to step Merge: 003F91
- to stream PascalFrancis, to step Corpus: 000E09
- to stream PascalFrancis, to step Curation: 001114
- to stream PascalFrancis, to step Checkpoint: 000D07
- to stream Main, to step Merge: 004057
- to stream PubMed, to step Corpus: 001765
- to stream PubMed, to step Curation: 001765
- to stream PubMed, to step Checkpoint: 001765
- to stream Ncbi, to step Merge: 002646
- to stream Ncbi, to step Curation: 002646
- to stream Ncbi, to step Checkpoint: 002646
- to stream Main, to step Merge: 003E62
- to stream Main, to step Curation: 003976
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases</title><author><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G" last="Walker">Douglas G. Walker</name></author><author><name sortKey="Terai, Kazuhiro" sort="Terai, Kazuhiro" uniqKey="Terai K" first="Kazuhiro" last="Terai">Kazuhiro Terai</name></author><author><name sortKey="Matsuo, Akinori" sort="Matsuo, Akinori" uniqKey="Matsuo A" first="Akinori" last="Matsuo">Akinori Matsuo</name></author><author><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G" last="Beach">Thomas G. Beach</name></author><author><name sortKey="Mcgeer, Edith G" sort="Mcgeer, Edith G" uniqKey="Mcgeer E" first="Edith G" last="Mcgeer">Edith G. Mcgeer</name></author><author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2E7AC6F53C260874E27058A3EF0823895208CCBC</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S0006-8993(98)00132-2</idno><idno type="url">https://api-v5.istex.fr/document/2E7AC6F53C260874E27058A3EF0823895208CCBC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002549</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002549</idno><idno type="wicri:Area/Istex/Curation">002549</idno><idno type="wicri:Area/Istex/Checkpoint">001534</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001534</idno><idno type="wicri:doubleKey">0006-8993:1998:Walker D:immunohistochemical:analyses:of</idno><idno type="wicri:Area/Main/Merge">003F91</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0352074</idno><idno type="wicri:Area/PascalFrancis/Corpus">000E09</idno><idno type="wicri:Area/PascalFrancis/Curation">001114</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D07</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D07</idno><idno type="wicri:doubleKey">0006-8993:1998:Walker D:immunohistochemical:analyses:of</idno><idno type="wicri:Area/Main/Merge">004057</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9622624</idno><idno type="wicri:Area/PubMed/Corpus">001765</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001765</idno><idno type="wicri:Area/PubMed/Curation">001765</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001765</idno><idno type="wicri:Area/PubMed/Checkpoint">001765</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001765</idno><idno type="wicri:Area/Ncbi/Merge">002646</idno><idno type="wicri:Area/Ncbi/Curation">002646</idno><idno type="wicri:Area/Ncbi/Checkpoint">002646</idno><idno type="wicri:doubleKey">0006-8993:1998:Walker D:immunohistochemical:analyses:of</idno><idno type="wicri:Area/Main/Merge">003E62</idno><idno type="wicri:Area/Main/Curation">003976</idno><idno type="wicri:Area/Main/Exploration">003976</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases</title><author><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G" last="Walker">Douglas G. Walker</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry and Neurodegenerative Disease Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>1Present address: Sun Health Research Institute, Sun City, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Terai, Kazuhiro" sort="Terai, Kazuhiro" uniqKey="Terai K" first="Kazuhiro" last="Terai">Kazuhiro Terai</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry and Neurodegenerative Disease Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>2Present address: Yamanouchi Pharmaceutical Company</wicri:regionArea></affiliation></author><author><name sortKey="Matsuo, Akinori" sort="Matsuo, Akinori" uniqKey="Matsuo A" first="Akinori" last="Matsuo">Akinori Matsuo</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry and Neurodegenerative Disease Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>3Present address: Department of Neurology, Kyoto University</wicri:regionArea><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName><orgName type="university">Université de Kyoto</orgName></affiliation></author><author><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G" last="Beach">Thomas G. Beach</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Department of Pathology, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>4Present address: Sun Health Research Institute, Sun City, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Mcgeer, Edith G" sort="Mcgeer, Edith G" uniqKey="Mcgeer E" first="Edith G" last="Mcgeer">Edith G. Mcgeer</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry and Neurodegenerative Disease Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry and Neurodegenerative Disease Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country><wicri:regionArea>Corresponding author. Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">794</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="181">181</biblScope><biblScope unit="page" to="187">187</biblScope></imprint><idno type="ISSN">0006-8993</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Cell Survival (physiology)</term><term>Cell death</term><term>Dopamine (analysis)</term><term>Dopaminergic</term><term>Dopaminergic neuron</term><term>Female</term><term>Fibroblast Growth Factor 1 (analysis)</term><term>Fibroblast growth factor</term><term>Human</term><term>Humans</term><term>Immunohistochemistry</term><term>Locus niger</term><term>Male</term><term>Middle Aged</term><term>Neurodegeneration</term><term>Neuron</term><term>Neurons (chemistry)</term><term>Neurotrophic factor</term><term>Parkinson Disease (metabolism)</term><term>Parkinson disease</term><term>Reference Values</term><term>Substantia Nigra (chemistry)</term><term>Substantia Nigra (cytology)</term><term>Tyrosine kinase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine</term><term>Fibroblast Growth Factor 1</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cell Survival</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Male</term><term>Middle Aged</term><term>Reference Values</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Facteur croissance fibroblaste</term><term>Facteur neurotrophique</term><term>Homme</term><term>Immunohistochimie</term><term>Locus niger</term><term>Mort cellulaire</term><term>Neurone dopaminergique</term><term>Parkinson maladie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The use of neurotrophic growth factors as a means of preventing loss of the dopaminergic (DA) neurons in the substantia nigra (SN) is becoming an accepted treatment strategy for Parkinson's disease (PD). In earlier studies, we showed that there was a selective loss of basic fibroblast growth factor (bFGF) immunoreactivity in DA neurons of the SN in PD suggesting that a deficiency of bFGF might contribute to cell death. As a preliminary step to assessing the potential for using bFGF or its analogs as therapeutic agents, the expression of fibroblast growth factor receptor-1 (FGFR-1) in the SN of normal and PD cases was investigated immunohistochemically. FGFR-1 immunoreactivity could be detected in DA neurons of the SN in young and old neurologically normal cases with an apparent decline with age. FGFR-1 immunoreactivity was also detected in many of the residual SN neurons in most of the idiopathic PD cases. These results indicate that FGFR-1 immunoreactivity, and possibly FGF binding activity, is retained in DA neurons in PD.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Japon</li><li>États-Unis</li></country><region><li>Arizona</li><li>Région du Kansai</li></region><settlement><li>Kyoto</li></settlement><orgName><li>Université de Kyoto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G" last="Walker">Douglas G. Walker</name></noRegion><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G" last="Beach">Thomas G. Beach</name><name sortKey="Matsuo, Akinori" sort="Matsuo, Akinori" uniqKey="Matsuo A" first="Akinori" last="Matsuo">Akinori Matsuo</name><name sortKey="Mcgeer, Edith G" sort="Mcgeer, Edith G" uniqKey="Mcgeer E" first="Edith G" last="Mcgeer">Edith G. Mcgeer</name><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L" last="Mcgeer">Patrick L. Mcgeer</name><name sortKey="Terai, Kazuhiro" sort="Terai, Kazuhiro" uniqKey="Terai K" first="Kazuhiro" last="Terai">Kazuhiro Terai</name></country><country name="États-Unis"><region name="Arizona"><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G" last="Walker">Douglas G. Walker</name></region><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G" last="Beach">Thomas G. Beach</name></country><country name="Japon"><noRegion><name sortKey="Terai, Kazuhiro" sort="Terai, Kazuhiro" uniqKey="Terai K" first="Kazuhiro" last="Terai">Kazuhiro Terai</name></noRegion><name sortKey="Matsuo, Akinori" sort="Matsuo, Akinori" uniqKey="Matsuo A" first="Akinori" last="Matsuo">Akinori Matsuo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003976 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003976 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2E7AC6F53C260874E27058A3EF0823895208CCBC
|texte= Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases
}}
| This area was generated with Dilib version V0.6.29. |  |